Newleos Ther­a­peu­tics

Generalized anxiety disorder, social anxiety disorder, and substance use disorders are among the most prevalent and under­treated neuropsy­chi­atric problems worldwide. Newleos is developing next-generation oral small-molecule therapies for all of these conditions, starting with a drug that boosts the GABA system in the amygdala, potentially delivering calming effects exactly where they’re needed, without side effects like sedation or dependence.